Among all vaccine breakthrough cases, 84% received the BNT162b2 COVID-19 vaccine (Pfizer/BioNTech), 13% received the mRNA-1273 vaccine (Moderna), and 2% received the JNJ-78436735 vaccine (J&J/Janssen). Again, this is a reflection of the high proportion of BNT162b2 vaccinations in the U.S. health system.
The majority of patients with delta variant infection had a recent travel history to countries with highly prevalent delta cases. This indicates that multiple virus introduction events are responsible for the current outbreak of the delta variant in Houston.